key: cord-0902697-hmr9aad0
authors: Venkatesulu, Bhanu P; Lester, Scott; Hsieh, Cheng-En; Verma, Vivek; Sharon, Elad; Ahmed, Mansoor; Krishnan, Sunil
title: Low-dose radiation therapy for COVID-19 – promises and pitfalls
date: 2020-11-19
journal: JNCI Cancer Spectr
DOI: 10.1093/jncics/pkaa103
sha: 6a8c9ddab62baa0ee1a5bd79e6b1e60afd3dbaf6
doc_id: 902697
cord_uid: hmr9aad0

The coronavirus disease-2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-CoV-2) has exacted an enormous toll on healthcare systems worldwide. The cytokine storm that follows pulmonary infection is causally linked to respiratory compromise and mortality in the majority of patients. The sparsity of viable treatment options for this viral infection and the sequelae of pulmonary complications have fueled the quest for new therapeutic considerations. One such option, the long-forgotten idea of using low dose radiation therapy (LDRT), has recently found renewed interest in many academic centers. We outline the scientific and logistical rationale for consideration of this option and the mechanistic underpinnings of any potential therapeutic value, particularly as viewed from an immunological perspective. We also discuss the preliminary and/or published results of prospective trials examining LDRT for COVID-19.

Coronaviruses belong to a family of RNA viruses that cause diseases in animals and less commonly in humans. However, seven coronaviruses are known to infect humans; two alpha coronaviruses, 229E and NL63, and five beta coronaviruses, OC43, HKU1, MERS-CoV (Middle East Respiratory Syndrome), SARS-CoV (Severe Acute Respiratory Syndrome), and SARS-CoV-2. The human coronaviruses were initially identified in the early 1960s coinciding with the discovery of the first anti-viral drug idoxuridine. Since then, the SARS and MERS outbreaks of 2002-2003 and 2012, respectively, have brought these viruses back into focus owing to the estimated case fatality rates of 10% and 30%, respectively. December 2019 heralded the dawn of a novel rapidly spreading virus from the coronavirus family, the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) 1 , that has (at the time of writing) infected 21 million people around the world, leading to nearly 750,000 deaths from coronavirus disease 2019 (COVID-19) 2,3 . The case fatality rate has ranged from 1-10% in different healthcare settings for the general public infected with SARS-CoV-2, 10-20% in hospitalized oxygendependent patients, and even higher in intubated patients [4] [5] [6] [7] .

Despite the many years since the original outbreaks of these viruses, the only drugs that have shown a modest clinical benefit are remdesivir and dexamethasone. The Adaptive COVID-19 Treatment Trial (ACTT-1) study, a double-blind randomized placebo-controlled trial of remdesivir in hospitalized COVID-19 patients with lower respiratory infection, a 10-day course of remdesivir resulted in shorter recovery time (median 11 vs. 15 days) and no improvement in overall survival albeit a trend towards a lower 14-day mortality rate (7.1% vs. 11.9%) than placebo 8 . A preprint report of the RECOVERY trial which randomized 6425 hospitalized COVID-19 patients 2:1 to standard of care vs. 6mg dexamethasone daily for up to 10 days noted that steroid treatment statistically significantly reduced 28-day mortality in patients undergoing invasive mechanical ventilation (29.0% vs. 40 .7%) and those requiring oxygen (21.5% vs. 25%) 9 . Multiple treatment strategies have been evaluated for COVID-19 including chloroquine and hydroxychloroquine (membrane fusion and endocytosis inhibitors), arbidol (viral envelope membrane fusion inhibitor), remdesivir, ribavirin, and favipiravir (viral RNA dependent RNA polymerase inhibitors), lopinavir and darunavir (chymotrypsin-like protease inhibitors), and tocilizumab and sarilumab (interleukin-6 inhibitors) 10 . None of these pharmacological interventions has statistically significantly reduced the intensive care admission rates, mortality rates, or improved any measurable outcomes. As a result, there is a pressing need for newer and/or alternative treatment strategies.

One consideration is to revisit the long-forgotten idea of using low dose radiation therapy (LDRT) for patients with lobar and interstitial pneumonia. Historically, from 1905 to the mid-1940s, LDRT was used in the treatment of non-resolving pneumonias, and anecdotal evidence suggests that this may have improved survival and provided rapid palliation of respiratory symptoms 11 . LDRT was rightly supplanted by the development of antibiotic and supportive medications. However, the lack of effective pharmacotherapy for this SARS-CoV-2 has prompted a reassessment of this old paradigm. Although the mechanism of action is yet to be defined, evidence from multiple contemporary preclinical and clinical experiences with LDRT could be used to generate testable hypotheses in the current COVID-19 crisis. In this review we outline the rationale for considering use of LDRT in moderately symptomatic patients with SARS-CoV-2 infection.

SARS-CoV-2 is transmitted through aerosol spread, whereby the virus gains entry into cells through the angiotensin-converting enzyme carboxypeptidase (ACE2) and the transmembrane protease serine (TMPRSS) cell surface receptors; these are highly expressed in the nasal mucosa, type 2 pneumocytes, and enteral goblet cells 12 . Viral entry coupled with rapid replication within cells results in pattern recognition receptors (PRR) sensing viral nucleic acid motifs. In addition to nucleic acid motifs, other hallmarks of the pathogen-associated molecular patterns (PAMPs) sensed by PRRs are structural proteins like the nucleocapsid, spike glycoproteins, membrane and envelope proteins, and non-structural proteins since they are broadly shared by different viruses and contribute to infectivity. Sensing of PAMPs by PRRs culminates in transcription of a variety of proinflammatory interferon regulatory factors (IRFs) and nuclear factor kappa B (NF-κB). This leads to the upregulation of type I and III interferons (IFN-I and IFN-III) and interferon stimulated genes (ISGs) as well as transmigration and homing of leukocytes mediated by chemokine secretion 13, 14 Consistent with this notion of unrestrained inflammation, the respiratory complications arising from COVID-19 have been mechanistically correlated with macrophage polarization to the proinflammatory M1 phenotype 15 . Autopsy studies of patients with severe SARS-CoV-2 infection as well as necropsy of experimentally infected non-human primates have documented immune-mediated injury to alveolar epithelial cells, hyperplasia of type II pneumocytes with hyaline membrane formation accompanied by fibroblastic consolidation, and diffuse alveolar damage 16, 17 .

A cardinal hematological feature that is also a prognostic factor for COVID-19 is lymphopenia.

Notably, elevated IL-6 and serum C-reactive protein (triggered by IL-6) are markers for clinical deterioration and ventilatory support in COVID-19. Elevated levels of IL-6 lead to downstream signaling via JAK (Janus kinase) and STAT3 (signal transducer and activator of transcription 3) activation, which in turn leads to activation of neutrophils, macrophages, and natural killer (NK) cells 18, 19 . In a study of 522 patients from China assessing the immune profile of patients with COVID-19, researchers reported that in patients with severe disease, the total T cell count (including both CD4+ and CD8+ subsets) were severely reduced. Importantly, this also correlated with poorer survival outcomes. There was also a reciprocal negative correlation between T cell count and the serum concentration of cytokines such as IL-6, IL-10, and TNF-α. These findings suggest that severe T cell exhaustion and widespread cytokine activation may be prime causes of mortality in patients with severe COVID-19 disease 20 .

From a clinical standpoint, patients with SARS-CoV-2 infection can present with diverse manifestations ranging from asymptomatic cases to mild symptomatology with fever, cough, and myalgia to more overt symptomatology with pneumonia, sepsis, acute respiratory distress syndrome, and respiratory failure. Patients with mild disease usually have minimal symptoms, such as fever, cough, myalgia and diarrhea with spontaneous resolution of symptoms. However, patients with moderate or severe disease are usually hospitalized and require close monitoring. Individuals with severe disease have increasing oxygen requirements (oxygen saturation <94% on room air) with elevated interleukin-6, Creactive protein, d-dimer, and ferritin; imaging findings often reveal infiltrates scattered throughout more than 50% of the lung. Older patients and those with comorbidities such as diabetes mellitus, hypertension, obesity, cardiovascular disease, and cancer are at highest risk of requiring ventilator support and dying secondary to acute respiratory distress syndrome 21 . Some evidence suggests that a dysfunctional and compromised immune response in patients with pre-existing comorbidities might explain the greater mortality and morbidity seen in these patients 18 .

Radiation is a double-edged sword with regard to the immune system; low-and high-dose RT have differential effects on the immune subsets. In the preclinical context, LDRT exerts effects on endothelial cells, leukocytes, macrophages, and dendritic cells. Collectively, these serve to create an antiinflammatory milieu, as mechanistically described below.

Endothelial cells play an important role in regulating inflammation through expression of cell surface adhesion molecules (e.g. E-selectin) that contribute to leukocytic homing to inflamed vessels. (TGF-β1) 22, 23 . Rodel also reported that LDRT between 0.5-1 Gy caused a statistically significant downregulation in CCL20 release (which normally plays an important role in the transmigration of B cells through the inflamed endothelium), which in turn is modulated by TGF-β1. This downregulation in CCL20 therefore correlated with reduction in leukocytic adhesion to endothelial cells, as downregulation of CCL20 prevents leukocyte chemotaxis to the site of injury 24 .

LDRT is also known to induce apoptosis of PBMCs, resulting in reduced TNF-α and IL-1 production, reduced L-selectin expression, and increased anti-inflammatory cytokine IL-10 production. was downregulated (resulting in reduction of nitric oxide production), whereas upregulation of iNOS was seen with doses more than 1.25 Gy. These reports suggest that lower doses of LDRT drive an antiinflammatory M2 phenotype by suppressing iNOS, whereas higher LDRT doses lead to a proinflammatory activated M1 macrophage phenotype with iNOS pathway activation 31 (Figure 1 ).

These results are consistent with the well-recognized phenomenon of hyper-radiation sensitivity (HRS) where a biphasic response is seen with LDRT. Mammalian cell lines have shown that single doses of LDRT of less than 10 cGy result in heightened sensitivity to radiation and that radiation doses beyond 0.5 Gy result in relative radioresistance 32 . In normal cells such as skin and peripheral blood lymphocytes, 0.5 Gy causes ATM autophosphorylation resulting in activation of DNA repair programs; however, in cancer cells the dose to activate ATM pathways is >1 Gy. The evolving evidence suggests that HRS is due to a lack of activation of ATM autophosphorylation pro-survival pathways. Based on this preclinical evidence, HRS has been used in the clinic to prime cells for greater efficacy and less toxicity when combined with chemotherapy. Clinical trials have been completed in a number of disease sites including head and neck, recurrent ovarian, pancreatic and small bowel, endometrial, breast, recurrent/progressive brain, and recurrent lung cancers 33 and as an experimental arm with dual checkpoints in an ongoing study in metastatic non-small cell lung cancer (NCT02888743).

On the other hand, some evidence suggests that LDRT may prime and activate macrophages. Consistent with this mechanistic uncertainty is a preclinical report from the 1940s suggesting that mortality from experimental swine influenza viral pneumonias in mice was statistically significantly reduced (by a third) when they were treated with x-ray therapy (100 r) 48 hours before inoculation of the virus but not when treatment was initiated 24 hours after inoculation 36 . The explanation offered was that established viral pneumonias are more refractory to treatment and that there is a lag of ~48 hours for radiation to exert its maximal effect via activation of reticuloendothelial cells for better phagocytosis.

Clearly, a nuanced understanding of lung tissue and immune biology, radiation dose-volume considerations that drive clinicopathological changes, mechanisms of injury, and biomarkers that predict the course of disease are direly needed 37 . Given sufficient time, the scientific rationale and mechanistic underpinnings of LDRT undoubtedly need to be fortified by systematic preclinical studies before advancing to well-designed randomized clinical trials with correlative endpoints and predictive biomarkers. This desire for sound preclinical scientific evidence must be balanced against the difficulty of generating mouse models of SAR-CoV2 pneumonia in a BSL3 laboratory, the practical and ethical challenges of co-locating radiation facilities and these BSL3 laboratories, and the unproven translatability of these models to human disease.

More than 700 patients have been reported in historical medical publications as having received LDRT for pneumonias that failed to abate after other therapies. In the largest series of LDRT for pneumonia, Powell et al. noted that x-ray therapy for lobar pneumonia and bronchopneumonia reduced the mortality rate to 5% and 13%, respectively, as compared to 30% seen in the 1930s. The response to therapy in most cases was rapid, with resolution of symptoms within hours 38, 39 . Oppenheimer reported clinical improvement of interstitial pneumonias in 33 of 36 pediatric patients as well as 45 of 56 adult patients treated with 30-90 Roentgen (~0.3-0.7 Gy), with earlier treatment resulting in better outcomes than when treatment was delayed by over two weeks 11, 40 . Additionally, leukocyte counts did not decrease following LDRT for pneumonia even in the setting of pre-existing leukopenia. Notably, the pulmonary consolidation disappeared within 3-5 days after radiation therapy. However, these studies were observational single-arm studies without a control group, hence burdened by unavoidable limitations due to their retrospective nature. Moreover, the studies predate the antiviral and antibiotic era, the x-ray therapy used was primitive compared to contemporary radiation therapy, and these studies did not delineate the correlates of response to therapy. As a result, not surprisingly, the advent of sulfonamide antibiotics in the early 1940s eroded interest in x-ray therapy for pneumonias.

The foregoing accounts of preclinical and clinical evidence and rationale for considering LDRT for COVID-19 provide a glimpse of the promises and pitfalls associated with advocating for LDRT during the current health crisis.

LDRT-related toxicities are expected to be mild, as there is a long-standing precedent for the use of whole lung radiation of 5-8 fractions of 1.5 Gy per fraction in Ewing's sarcoma and Wilms tumor, along with whole body radiation for bone marrow ablation in transplant conditioning regimens. These are generally considered safe and have an acceptable safety profile 41, 42 . Moreover, doses as low as 0.3-0.6 Gy are unlikely to cause any appreciable early side effects like pneumonitis, esophagitis, myelitis, cardiac injury, or late effects like lung fibrosis, scarring, or second malignancies. The theoretical benefits of LDRT, based on the mechanisms discussed earlier, relate to possible effects on hematological cells in the circulation, in transit in the heart, or resident cells in the spleen/bone marrow and/or endothelial cells 43, 44 .

If the proper subset of these cells could be eliminated, applying LDRT might be a meaningful exercise. It could be argued that in the midst of a global pandemic with no known intervention (aside from remdesivir and dexamethasone) that has statistically significantly reduced severity of symptoms or mortality to date, the use of LDRT with contemporary radiation techniques inclusive of CT-based planning and modern radiation dosimetry may offer a simple and readily accessible intervention. While there is always a concern with use of radiation for any clinical disease, the cost of not receiving these treatments may be far worse than that of receiving these treatments, especially when LDRT is reserved for moderately symptomatic (oxygen-dependent) and severely affected (intubated) patients who have a mounted a dysfunctionally exuberant immune response and for whom the risk-benefit ratio is favorable. Mounting evidence suggests that severe COVID infections are associated with elevated neutrophil-to-lymphocyte ratios, CRP and IL-6, and reduced lymphocyte and monocyte counts but a relative increase in exhausted (Tim3 and PD1 positive) CD8+ T cells and highly inflammatory CD14+16+ monocytes 45 .

The primary concern with LDRT is the potential lack of efficacy as detailed in some reports above. Because lymphocytes are also required to mount an immune response against COVID-19, excessive inactivation of lymphocytes may theoretically impair the ability to mount a counter-offensive to the virus and hence hasten mortality. Undoubtedly, the dose and volume of LDRT would influence the degree of lymphocytic inactivation, but currently there are no validated countermeasures for radiationinduced lymphopenia. Furthermore, there may be a theoretical risk of radiation-induced mutations of the viral genome which can potentially induce selection pressure leading to unintended and undesirable evolutionary changes during viral replication. Another disadvantage of LDRT use for the current global health pandemic relates to logistical aspects of RT delivery. Transportation of a known COVID-19 patient to radiotherapy departments, along with the process of CT simulation and RT delivery can risk infection of staff and other patients. Moreover, the time required to adequately sterilize RT equipment between patients may limit the ability to treat other patients in a given time frame. Many clinicians and radiation therapists may also not be comfortable with treating intubated patients. For all these reasons, consideration of LDRT for COVID-19 is logistically, mechanistically, and ethically challenging, warranting careful consideration of the pros and cons of invoking such a treatment approach.

Nevertheless, multiple studies across several nations are now underway to assess the impact of LDRT ( Table 1) . Two of these are available in pre-print or print format. A preprint version of the trial from Emory University evaluated 1.5 Gy whole lung LDRT in 10 hospitalized and oxygen-dependent COVID-19 patients. The median time to clinical recovery was 3 days compared to 12 days for 10 matched control patients, 6 of whom received COVID-directed therapy (p=0.05) 46 . This was also associated with a shorter time to hospital discharge (12 vs. 20 days), lower intubation rates (10% vs. 

The data underlying this article are available in the article. 

Low dose radiation therapy LEGEND Figure 1 --FINAL

A Novel Coronavirus from Patients with Pneumonia in China

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

2019-nCoV, CSSE. Coronavirus 2019-nCoV Global Cases by

Cross-Country Comparison of Case Fatality Rates of COVID-19/SARS-COV-2

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Oppenheimer A: Roentgen therapy of "virus" pneumonia

Thu Elizabeth Duong et al: SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues

Double-Stranded RNA Sensors and Modulators in Innate Immunity

Innate immune recognition

COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

The trinity of COVID-19: immunity, inflammation and intervention

Cytokine release syndrome in severe COVID-19

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease

Mild or Moderate Covid-19

The induction of TGF-beta(1) and NF-kappaB parallels a biphasic time course of leukocyte/endothelial cell adhesion following low-dose Xirradiation

Anti-inflammatory effect of low-dose X-irradiation and the involvement of a TGF-beta1-induced down-regulation of leukocyte/endothelial cell adhesion

The anti-inflammatory effect of low-dose radiation therapy involves a diminished CCL20 chemokine expression and granulocyte/endothelial cell adhesion

Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice

Activation-induced cell death and total Akt content of granulocytes show a biphasic course after low-dose radiation

Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro

0.5 Gy gamma radiation suppresses production of TNFalpha through up-regulation of MKP-1 in mouse macrophage RAW264.7 cells

Low dose ionising radiation leads to a NF-κB dependent decreased secretion of active IL-1β by activated macrophages with a discontinuous dose-dependency

The effects of low-dose X-irradiation on the oxidative burst in stimulated macrophages

Mechanisms of the anti-inflammatory activity of low-dose radiation therapy

Low-dose hypersensitivity: current status and possible mechanisms

Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

A systematic review of the influence of radiationinduced lymphopenia on survival outcomes in solid tumors

The effect of Roentgen therapy on experimental virus pneumonia

Normal tissue protection for improving radiotherapy: Where are the Gaps?

The treatment of acute pneumonias with roentgen rays

Oppenheimer A: Roentgen therapy of interstitial pneumonia

Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment

Total Body Irradiation: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG)

Radiation-Induced Endothelial Vascular Injury: A Review of Possible Mechanisms

Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?

Immune Response, Inflammation, and the Clinical Spectrum of COVID-19

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia. medRxiv

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial